$82.63▴ 3.44%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$2.26cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+20.5%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 51% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
ANI Pharmaceuticals, Inc. turns 226¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year.
Key numbers
Valuation
EPS (TTM)$3.94
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin10.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$923.71M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days3 articles
2 bullish1 neutral0 bearish
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.